Anil Vachani

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center
Attending Physician, Philadelphia Veterans Administration Medical Center
Director of Clinical Research, Section of Interventional Pulmonology and Thoracic Oncology, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine
Director of Bronchoscopy, Philadelphia VA Medical Center
Director, Lung Nodule Program, Perelman School of Medicine, Univeristy of Pennsylvania
Associate Director, Masters in Translational Research Program, ITMAT Educational Programs, Perelman School of Medicine, University of Pennsylvania
Co-Director Lung Cancer Screening Program, Perelman School of Medicine, University of Pennslvania
Department: Medicine

Contact information
Pulmonary, Allergy, and Critical Care Division
University of Pennsylvania School of Medicine
Suite 216, Stemmler Hall
3450 Hamilton Walk
Philadelphia, PA 19104
Office: 215.573.7931
B.S. (Genetics)
University of California, Berkeley, 1992.
B.A. (Economics)
University of California, Berkeley, 1992.
M.D. (Medicine)
University of California, San Francisco, 1996.
M.S. (Clinical Epidemiology)
University of Pennsylvania, Perelman School of Medicine, 2013.
Post-Graduate Training
Categorical Internal Medicine Residency Program, Hospital of the University of Pennsylvania, Department of Medicine , 1996-1999.
Fellowship, Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Department of Medicine, 2000-2004.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Dr. Vachani is interested in the molecular epidemiology of lung cancer and in discovery and validation of early detection biomarkers for thoracic malignancies. His research ranges from animal models to human translational studies and includes observational and correlative studies in early and late phase clinical trials.

Selected Publications

Thompson JC, Aggarwal C, Wong J, Nimgaonkar V, Hwang WT, Andronov M, Dibardino DM, Hutchinson CT, Ma KC, Lanfranco A, Moon E, Haas AR, Singh AP, Ciunci CA, Marmarelis M, D'Avella C, Cohen JV, Bauml JM, Cohen RB, Langer CJ, Vachani A, Carpenter EL: Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study. JTO Clin Res Rep 3(4): 100301, Mar 2022.

Kim RY, Rendle KA, Mitra N, Saia CA, Neslund-Dudas C, Greenlee RT, Burnett-Hartman AN, Honda SA, Simoff MJ, Schapira MM, Croswell JM, Meza R, Ritzwoller DP, Vachani A: Racial Disparities in Adherence to Annual Lung Cancer Screening and Recommended Follow-up Care: A Multicenter Cohort Study. Ann Am Thorac Soc Feb 2022.

Ritzwoller DP, Meza R, Carroll NM, Blum-Barnett E, Burnett-Hartman AN, Greenlee RT, Honda SA, Neslund-Dudas C, Rendle KA, Vachani A.: Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems. JAMA Netw Open 4: e2128176, Oct 2021.

Kim RY, Li Y, Marmarelis ME, Vachani A.: Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. Lung Cancer 159: 107-110, Sep 2021 Notes: doi: 10.1016/j.lungcan.2021.06.017.

Vachani A, Maldonado F, Laxmanan B, Kalsekar I, Murgu S.: The Impact of Alternative Approaches to Diagnostic Yield Calculation in Studies of Bronchoscopy. Chest Page: Online ahead of print, Sep 2021 Notes: doi: 10.1016/j.chest.2021.08.074.

Burnett-Hartman AN, Carroll NM, Honda SA, Joyce C, Mitra N, Neslund-Dudas C, Olaiya O, Rendle KA, Schnall MD, Vachani A, Ritzwoller DP.: Community-based Lung Cancer Screening Results in Relation to Patient and Radiologist Characteristics: the PROSPR Consortium. Ann Am Thorac Soc Page: Online ahead of print, Sep 2021 Notes: doi: 10.1513/AnnalsATS.202011-1413OC.

Kim RY, Mitra N, Bagley SJ, Marmarelis ME, Haas AR, Rendle KA, Vachani A.: Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma. JTO Clinical and Research Reports 2(6): 100188, Jun 2021.

Schapira MM, Rodriguez KL, Chhatre S, Fraenkel L, Bastian LA, Kravetz JD, Asan O, Akers S, Vachani A, Prigge JM, Meline J, Ibarra JV, Corn B, Kaminstein D.: When Is a Harm a Harm? Discordance between Patient and Medical Experts' Evaluation of Lung Cancer Screening Attributes. Med Decis Making 41: 317-328, Apr 2021.

Gould MK, Altman DE, Creekmur B, Qi L, de Bie E, Golden S, Kaplan CP, Kelly K, Miglioretti DL, Mularski RA, Musigdilok VV, Smith-Bindman R, Steltz JP, Wiener RS, Aberle DR, Dyer DS, Vachani A.: Guidelines for the Evaluation of Pulmonary Nodules Detected Incidentally or by Screening: A Survey of Radiologist Awareness, Agreement, and Adherence From the Watch the Spot Trial. J Am Coll Radiol 18(4): 545-553, April 2021.

Tanner NT, Springmeyer SC, Porter A, Jett JR, Mazzone P, Vachani A, Silvestri GA.: Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest 159: 1283-1287, Mar 2021.

back to top
Last updated: 04/11/2022
The Trustees of the University of Pennsylvania